In comparison to constitutively active anti-EGFRvIII/EphA2/IL13Rα2 CAR T cells, synNotch-CAR T cells showed greater anti-tumor efficacy without off-tumor toxicity. This evidence concerns the gene IL13RA2 and neoplasm.